| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1038/NRCLINONC.2009.90 |
| P698 | PubMed publication ID | 19644536 |
| P50 | author | William David Foulkes | Q37829195 |
| Fleur Huang | Q60481498 | ||
| P2093 | author name string | Adrian Langleben | |
| Yael B Kushner | |||
| P2860 | cites work | Metastatic bone disease: clinical features, pathophysiology and treatment strategies | Q28202792 |
| BRCA1 and BRCA2: 1994 and beyond | Q34345297 | ||
| Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers | Q34579373 | ||
| Endocrine therapy plus zoledronic acid in premenopausal breast cancer. | Q34943802 | ||
| Platinum-based chemotherapy in metastatic breast cancer: current status. | Q35650449 | ||
| Improved survival in BRCA2 carriers with ovarian cancer | Q35828679 | ||
| Reducing breast cancer incidence in familial breast cancer: overlooking the present panorama. | Q35848789 | ||
| BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis | Q36493340 | ||
| Management of BRCA1/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. | Q36649227 | ||
| Lasting remission following multimodal treatment in a patient with metastatic breast cancer | Q40496470 | ||
| BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). | Q41056489 | ||
| BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays | Q42506232 | ||
| Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations | Q43520691 | ||
| Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and N | Q46378871 | ||
| Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chem | Q46916856 | ||
| Prophylactic cranial irradiation in advanced breast cancer: a case for caution | Q48862630 | ||
| BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes | Q57309394 | ||
| Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer | Q71261788 | ||
| Cancer: crossing over to drug resistance | Q80786850 | ||
| End of high-dose chemotherapy for high-risk breast cancer patients? | Q81183896 | ||
| Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years | Q83202996 | ||
| High-dose chemotherapy and autologous hematopoietic stem cell transplantation for metastatic breast cancer: a therapy whose time has passed | Q83365174 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| chemotherapy | Q974135 | ||
| P304 | page(s) | 488-492 | |
| P577 | publication date | 2009-08-01 | |
| P1433 | published in | Nature Reviews Clinical Oncology | Q641640 |
| P1476 | title | Eleven years disease-free: role of chemotherapy in metastatic BRCA2-related breast cancer | |
| P478 | volume | 6 |
| Q36101775 | Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management |
| Q26739366 | Cytotoxic and targeted therapy for hereditary cancers |
| Q35208929 | Drug therapy for hereditary cancers |
| Q30513982 | Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine |
| Q37933098 | Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers |
| Q33827045 | Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy |
| Q49829001 | Role of BRCA Mutations in the Modulation of Response to Platinum Therapy |
| Q37844487 | Studying therapy response and resistance in mouse models for BRCA1-deficient breast cancer |
| Q37897274 | Surviving metastatic breast cancer for 18 years: a case report and review of the literature |
| Q36755366 | Systemic treatment for hereditary cancers: a 2012 update |
Search more.